Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: AVES Country of Publication: Turkey NLM ID: 101522982 Publication Model: Print Cited Medium: Print ISSN: 1308-7649 (Print) Linking ISSN: 13087649 NLM ISO Abbreviation: J Int Adv Otol Subsets: MEDLINE
    • Publication Information:
      Publication: <2016- > : İstanbul : AVES
      Original Publication: Ankara : Mediterranean Society of Otology and Audiology
    • Subject Terms:
      Antibodies, Anti-Idiotypic/*therapeutic use ; Bone Conduction/*physiology ; Ear, Middle/*drug effects ; Otitis Media with Effusion/*drug therapy; Antibodies, Monoclonal/therapeutic use ; Bone-Anchored Prosthesis/adverse effects ; Ear, Middle/immunology ; Ear, Middle/pathology ; Eosinophilia/physiopathology ; Eosinophils/immunology ; Female ; Hearing Aids/adverse effects ; Hearing Loss/etiology ; Humans ; Immunologic Factors/therapeutic use ; Middle Aged ; Otitis Media with Effusion/complications ; Otitis Media with Effusion/immunology ; Treatment Outcome
    • Abstract:
      Eosinophilic otitis media (EOM) are intractable otitis media characterized by highly viscous secretions containing eosinophils in the middle ear. They are resistant to conventional medication and surgery. This condition occurs primarily in patients with bronchial asthma or allergic rhinitis and is often complicated by rhinosinusitis. Systemic and topical steroid therapies are effective treatments. However, long-term steroid therapy is often limited by a high risk of serious adverse effects. The use of topical steroids and otorrhea are bothersome when wearing hearing aids. Here, we report a case of intractable otitis media due to EOM. Otorrhea was controlled with topical steroids. Bone conduction hearing was stable for an extended period with anti-IgE monoclonal antibodies (omalizumab). An implantable bone conduction hearing aid was used for rehabilitation of conductive hearing loss.
    • References:
      J Allergy Clin Immunol. 2005 Mar;115(3):459-65. (PMID: 15753888)
      Curr Allergy Asthma Rep. 2008 Nov;8(6):525-30. (PMID: 18940145)
      Allergol Int. 2010 Sep;59(3):233-238. (PMID: 20657163)
      Auris Nasus Larynx. 2011 Aug;38(4):456-61. (PMID: 21251776)
      Otol Neurotol. 2012 Sep;33(7):1218-24. (PMID: 22825324)
      Case Rep Pulmonol. 2012;2012:340525. (PMID: 23227405)
      Otol Neurotol. 2013 Aug;34(6):1071-5. (PMID: 23598702)
      Eur Arch Otorhinolaryngol. 2017 Feb;274(2):1173-1177. (PMID: 27168402)
      N Engl J Med. 2017 Feb 16;376(7):e10. (PMID: 28199806)
    • Accession Number:
      0 (Antibodies, Anti-Idiotypic)
      0 (Antibodies, Monoclonal)
      0 (Immunologic Factors)
      0 (anti-IgE antibodies)
    • Publication Date:
      Date Created: 20180517 Date Completed: 20191010 Latest Revision: 20200225
    • Publication Date:
      20240829
    • Accession Number:
      PMC6354496
    • Accession Number:
      10.5152/iao.2018.4517
    • Accession Number:
      29764789